Global elimination of hepatitis C virus by 2030: why not?

Affiliations

¹ The Kirby Institute, University of New South Wales, Sydney, Australia. gdore@kirby.unsw.edu.au.
² The Kirby Institute, University of New South Wales, Sydney, Australia.

Gregory J Dore et al. Nat Med. 2020 Feb.

. 2020 Feb;26(2):157-160.

doi: 10.1038/s41591-019-0706-x.

¹ The Kirby Institute, University of New South Wales, Sydney, Australia. gdore@kirby.unsw.edu.au.
² The Kirby Institute, University of New South Wales, Sydney, Australia.

No abstract available

References

1. Choo, Q. L. et al. Science 244, 359–362 (1989). - DOI
1. Hajarizadeh, B., Grebely, J. & Dore, G. J. Nat. Rev. Gastroenterol. Hepatol. 10, 553–562 (2013). - DOI
1. Dore, G. J. & Feld, J. J. Clin. Infect. Dis. 60, 1829–1836 (2015). - DOI
1. World Health Organization. Global Health Sector Strategy on Viral Hepatitis, 2016–2021 (World Health Organization, Geneva, Switzerland, 2016).
1. Global Burden of Disease Collaborators. Lancet 390, 1151–1210 (2017). - DOI